UK NHS review finds benefit in combining PET/CT to assess breast cancer recurrence
This article was originally published in Clinica
Executive Summary
A review for the UK’s National Health Service of the use of positron emission tomography (PET) and computed tomography (CT) in prognosing breast cancer recurrence has found that the combination of the two technologies “offers improved diagnostic accuracy compared to conventional imaging tests”. However, “uncertainty remains around its use as a replacement for, rather than as an add-on to, existing technologies”, concluded a team of researchers from the West Midlands Health Technology Assessment Collaboration (WMHTAC) at the University of Birmingham. The systematic review, which appears in the current issue of the journal Health Technology Assessment, was conducted on behalf of the Evaluation, Trials and Studies Coordinating Centre (NETSCC) of the National Institute for Health Research (NIHR).